Max BioPharma Announces Key Update To Its Oxysterol Therapeutics Development Program
LOS ANGELES, July 10, 2017 /PRNewswire/ -- MAX BioPharma, Inc. (www.maxbiopharma.com) is pleased to announce that it has obtained promising positive results from its Proof of Concept study using one of its therapeutic candidates for intervention in osteoporosis. Data showed that in the rat ovariectomized model of human osteoporosis, oral administration of Oxy200, selected as a lead compound from the Company's Oxysterol Therapeutics® platform of proprietary oxysterols, significantly prevented bone loss and development of osteoporosis after 28 days of treatment, with no signs of adverse effects. This was associated with significant increases in bone mineral density and bone mineral content. The Company is now optimizing the compound for oral dosing and anticipates starting discussions with the FDA regarding the path to clinical trials and commercialization.
The Company's bone anabolic therapies, which may also exert anti-resorptive effects, are unique and distinguished from the market-leading anti-resorptive and bone anabolic therapies, and MAX BioPharma is poised to complete development of these highly disruptive treatments to meet the significant unmet medical need. This work has been supported so far by generous grants from the National Institutes of Health, however, the next steps require additional resources. The Company is now seeking strategic partnerships with biotechnology and pharmaceutical companies that have the necessary expertise and resources to continue the development of oxysterols for osteoporosis intervention through clinical development to FDA approval and commercialization. Furthermore, based on its multiple positive findings in preclinical models of bone regeneration, the Company is seeking partnerships for developing its potent osteogenic oxysterol, Oxy133, for stimulation of localized bone formation in orthopedic indications, such as spine fusion. In addition, MAX BioPharma is in the process of raising a series A financing round to support the advancement of its therapeutic development programs.
About MAX BioPharma, Inc.
MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company will be a leader in the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous indications. MAX BioPharma's first success based on small molecule lipids has contributed to the discovery of novel osteogenic oxysterol compounds that target multipotent mesenchymal cells, including mesenchymal stem cells, to induce the formation of bone-forming osteoblasts and bone. The company is translating this technology into the next generation of therapeutic agents for stimulation of bone formation, locally and systemically, in indications such as spinal fusion, non-union fractures, and osteoporosis. MAX BioPharma is also pursuing the development of small molecule oxysterols that function as anti-tumorigenic Hedgehog pathway antagonists that will be more effective than currently known antagonists in treating a variety of Hedgehog pathway-related cancers, including pancreatic cancer, breast cancer, and hematologic malignancies. For more information please visit us at www.maxbiopharma.com
Media Contact: Farhad Parhami
fparhami@maxbiopharma.com
View original content:http://www.prnewswire.com/news-releases/max-biopharma-announces-key-update-to-its-oxysterol-therapeutics-development-program-300484987.html
SOURCE MAX BioPharma
